Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

Roche’s Perjeta secures NICE approval in adjuvant HER2+ metastatic breast cancer

February 15, 2019
Medical Communications, Sales and Marketing NICE, Perjeta, Roche, pharma

NICE has announced its decision to authorise the use of Roche’s Perjeta (pertuzumab) on the NHS for the treatment of …

News
shutterstock_273326141

NICE joins forces with Canadian peer to offer scientific advice to the pharma industry

February 6, 2019
Research and Development, Sales and Marketing CADTH, Canada, NICE, UK, pharma

NICE has announced a collaboration with its Canadian counterpart, the Canadian Agency for Drugs and Technology in Health (CADTH), with …

News
kymriah

Novartis’ CAR-T therapy Kymriah gets NICE green light in diffuse large B-cell lymphoma

February 1, 2019
Medical Communications, Sales and Marketing CAR-T, Cancer, Kymriah, NICE, Novartis, lymphoma, pharma

NICE has announced another momentous decision for lymphoma patients in England and Wales:, recommending Novartis’ chimeric antigen receptor T cell …

News
imp_pologne2

NICE recommends Pierre Fabre’s Braftovi in BRAF V600-mutated advanced melanoma

January 21, 2019
Sales and Marketing Braftovi, Cancer, NICE, Pierre Fabre, UK, melanoma, pharma

Braftovi (encorafenib), a BRAF kinase inhibitor developed by Pierre Fabre, has been awarded approval in combination with Mektovi (binimetinib) by …

News

Abbvie’s chronic lymphocytic leukaemia drug Venclytxo scores greenlight from NICE

January 18, 2019
Medical Communications, Sales and Marketing AbbVie, NHS, NICE, Venclyxto, leukaemia, pharma

A new recommendation from NICE means that thousands of patients in England and Wales will be able to receive Abbvie’s …

News

Eli Lilly’s Verzenios scores NICE recommendation for advanced breast cancer

January 17, 2019
Sales and Marketing Cancer, Eli Lilly, NICE, Verzenios, breast cancer, pharma

Breast cancer patients in England and Wales now have access to another treatment option, as NICE announces its recommendation of …

News

NICE rejects Novartis’ Aimovig migraine injection for NHS use

January 10, 2019
Sales and Marketing Aimovig, NICE, Novartis, migraine, pharma

It’s disappointing news for Novartis as NICE revealed that it had decided not to recommend Aimovig (erenumab) for routine NHS …

News
astrazeneca_sign_sky

NICE recommends AstraZeneca’s Fasenra as third treatment option for severe asthma

January 4, 2019
Medical Communications, Sales and Marketing AstraZeneca, Fasenra, NHS, NICE, UK, asthma, pharma

It’s good news for both asthma patients and AstraZeneca after UK drug watchdog NICE saw fit to recommend the drugmaker’s …

News

NICE recommends Lenvima as alternative first-line therapy for advanced liver cancer

December 19, 2018
Research and Development, Sales and Marketing Lenvima, NICE, UK, liver cancer, pharma

UK drug watchdog NICE has revealed that it has recommended Eisai’s Lenvima (lenvatinib) for use on the NHS in England …

News
gilead-sciences

NICE give go-ahead to Gilead’s Yescarta for adults with lymphoma

December 7, 2018
Medical Communications Cancer, Cost, Gilead, NHS, NICE, Yescarta, access

The NHS cost effectiveness body NICE has approved Gilead’s Yescarta for treatment of come adults with lymphoma. Gilead’s treatment will …

News

NICE approves Cimzia but blocks Ilumetri in treatment of psoriasis

December 4, 2018
Manufacturing and Production, Sales and Marketing Almirall, Cimzia, Ilumetri, NICE, UCB, UK, pharma, psoriasis

UK drug watchdog NICE has announced two new recommendations relating to medicines for the treatment of psoriasis, approving UCB Pharma’s …

News
institute_of_cancer_research

Cancer drug access for NHS patients is slowing, ICR reports

December 4, 2018
Manufacturing and Production, Research and Development, Sales and Marketing Cancer, ICR, Institute of Cancer Research, NHS, NICE, UK, pharma

A new report from the Institute of Cancer Research (ICR) has indicated that NHS patients in the UK are suffering …

News
opdivo_1_1

Opdivo to be made available to UK melanoma patients via the Cancer Drugs Fund

November 30, 2018
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, NICE, UK, melanoma, pharma

Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) is set to be made available to patients in the UK via the Cancer …

News

NICE recommends Bayer’s Stivarga for advanced hepatocellular carcinoma

November 29, 2018
Sales and Marketing Bayer, NICE, Stivarga, UK, pharma

The National Institute for Health and Care Excellence (NICE) has voiced its recommendation for Bayer’s Stivarga (regorafenib) for use on …

News

Cancer Drugs Fund to offer MSD’s Keytruda for lung cancer

November 22, 2018
Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NICE, UK, keytruda, pharma

MSD’s Keytruda (pembrolizumab) will now be made available via the Cancer Drugs Fund for patients in England, as NICE announces …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026